Skip to main content

End of Q3 update from REPROCELL (2022-23)

The year might be coming to a close, but we’re not winding down at REPROCELL. The final months of 2022 have brought new collaborations, partnerships, and successes to enrich your stem cell and drug discovery research. This includes our membership to the CIRM Industry Resource Partner Program and our latest agreement with the CDMO BioBridge global – both of which will make REPROCELL’s clinical iPSC technology and subsequent cell therapy manufacturing more accessible.

You can find a list of everything else we’ve been up to since October below:

  1. REPROCELL invests in Histocell, S.L. a Spain-based CDMO [PRESS RELEASE]
  2. Building economic resilience and unleashing productivity through digital innovation [NEWS]
  3. REPROCELL Inc. and JTB Corp. form a business alliance to provide Personal iPSC Service to domestic and overseas customers [PRESS RELEASE]
  4. REPROCELL’s Stemgent brings mRNA reprogramming to the clinical sector [BLOG]
  5. Everything we know about resistance arteries [BLOG]
  6. 4 ways ex vivo models offer Pharma better alternatives to animal testing [BLOG]
  7. Isolating PBMCs from whole blood using density gradient centrifugation [BLOG]

If you have any questions about our products and services, please reach out via our websiteWe hope that you enjoy the festive break and start back into 2023 rested and refreshed.

Subscribe to receive updates from REPROCELL